Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Hematopoietic stem cell remobilization with vinorelbine and filgrastim in AML

Bone Marrow Transplantation volume 52, pages 786–788 (2017)Cite this article

Subjects

High-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) to consolidate first CR is proposed for AML patients who have favorable- or intermediate-risk karyotype abnormalities.1, 2, 3 It provides substantial anti-leukemic efficacy without the morbidity and mortality of GvHD associated with allogeneic transplantation. Although successful mobilization of PBSC is a prerequisite for ASCT, mobilization failure in AML patients has been poorly studied so far.4 Moreover, alternative strategies for AML patients with mobilization failure are limited to harvesting stem cells from the bone marrow and there are inconveniences associated with this procedure. Also, very limited experience is available on the use of the CXCR4 antagonist plerixafor as a rescue strategy in AML patients.5

We have reported the use of the cytotoxic compound vinorelbine together with G-CSF as a fully ambulatory mobilization procedure allowing highly predictable collection of PBSC at day 8 in myeloma and lymphoma patients.6, 7, 8, 9 In this retrospective study, we explored the potential of vinorelbine together with G-CSF as a remobilization procedure in AML patients in first remission with primary mobilization failure after two cycles of intensive chemotherapy. Patients were treated according to the SAKK/HOVON-42, -92 or -102 protocols and underwent PBSC mobilization if the genomic-based risk assessment indicated good-risk, intermediate-risk (in the absence of an HLA-identical sibling donor), or bad-risk (in the absence of a sibling and an unrelated matched donor) AML. The study period included all eligible patients treated at the University Hospital of Bern, Switzerland between May 2005 and January 2015, and the clinical characteristics of the patients are summarized in Table 1. This study was approved by the local ethics committee of Bern, Switzerland (decision number #220/15).

Table 1 Clinical characteristics at diagnosis of AML patients with MF and with EM of PBSC
Full size table

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Zuckerman T, Beyar-Katz O, Rowe JM . Should autotransplantation in acute myeloid leukemia in first complete remission be revisited? Curr Opin Hematol 2016; 23: 88–94.

    Article  CAS  Google Scholar 

  2. Gorin NC, Giebel S, Labopin M, Savani BN, Mohty M, Nagler A . Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. Bone Marrow Transplant 2015; 50: 1495–1502.

    Article  CAS  Google Scholar 

  3. Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011; 118: 6037–6042.

    Article  CAS  Google Scholar 

  4. Bik To L, Levesque JP, Herbert KE . How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011; 118: 4530–4540.

    Article  Google Scholar 

  5. Stölzel F, Wermke M, Röllig C, Thiede C, Platzbecker U, Bornhäuser M . Mobilization of PML/RARalpha negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide. Haematologica 2010; 95: 171–172.

    Article  Google Scholar 

  6. Bargetzi MJ, Passweg J, Baertschi E, Schoenenberger A, Gwerder C, Tichelli A et al. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transplant 2003; 31: 99–103.

    Article  CAS  Google Scholar 

  7. Heizmann M, O'Meara AC, Moosmann PR, Heijnen IA, Zuberbühler M, Fernandez P et al. Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma. Bone Marrow Transplant 2009; 44: 75–79.

    Article  CAS  Google Scholar 

  8. Schmid A, Friess D, Mansouri Taleghani B, Keller P, Mueller BU, Baerlocher GM et al. Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leuk Lymphoma 2015; 56: 608–614.

    Article  CAS  Google Scholar 

  9. Keller S, Seipel K, Novak U, Mueller BU, Taleghani BM, Leibundgut K et al. Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. Leuk Res 2015; 39: 786–792.

    Article  CAS  Google Scholar 

  10. Von Grunigen I, Raschle J, Rusges-Wolter I, Mansouri Taleghani BM, Mueller BU, Pabst T . The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential. Leuk Res 2012; 36: 1325–1329.

    Article  Google Scholar 

  11. Wetzel D, Mueller BU, Mansouri Taleghani B, Baerlocher GM, Seipel K, Leibundgut K et al. Delayed haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemia. Br J Haematol 2015; 168: 268–273.

    Article  CAS  Google Scholar 

  12. Visani G, Lemoli R, Tosi P, Martinelli G, Testoni N, Ricci P et al. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. Bone Marrow Transplant 1999; 24: 467–472.

    Article  CAS  Google Scholar 

  13. Breems DA, Lowenberg B . Acute myeloid leukemia and the position of autologous stem cell transplantation. Semin Hematol 2007; 44: 259–266.

    Article  Google Scholar 

  14. Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J et al. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia 2015; 29: 1041–1050.

    Article  CAS  Google Scholar 

  15. Wang J, Ouyang J, Zhou R, Chen B, Yang Y . Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials. Acta Haematol 2010; 124: 61–71.

    Article  Google Scholar 

Download references

Acknowledgements

We thank the stem cell coordinating team, the stem cell data-management team, the members of the stem cell collection unit and members of the stem cell processing unit associated with the stem cell program at the University Hospital Berne for providing the data used in this analysis. Also, we thank all staff members involved in the care of the patients reported in this study. This study was supported by grants SNF-310030-143584 to TP.

Author contributions

VB performed the research, analyzed the data and wrote the paper; AH performed the research, analyzed the data, reviewed the manuscript and was involved in the final writing of the paper; KS analyzed the data, reviewed the manuscript and was involved in the final writing of the paper; BMT, GMB, UN, KL, YB and MB contributed relevant data, reviewed the manuscript and were involved in the final writing of the paper; and TP designed the research, analyzed the data and wrote the paper.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland

    V Blum, A D Heini, U Novak & T Pabst

  2. Department of Hematology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland

    B M Taleghani & G M Baerlocher

  3. Department of Clinical Research, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland

    G M Baerlocher & K Seipel

  4. Department of Pediatric Hemato-Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland

    K Leibundgut

  5. Institute of Pathology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland

    Y Banz

  6. Department of Hematology, Kantonsspital, Aarau, Switzerland

    M Bargetzi

Authors
  1. V Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A D Heini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U Novak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B M Taleghani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G M Baerlocher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Leibundgut
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Seipel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Banz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Bargetzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T Pabst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Pabst.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blum, V., Heini, A., Novak, U. et al. Hematopoietic stem cell remobilization with vinorelbine and filgrastim in AML. Bone Marrow Transplant 52, 786–788 (2017). https://doi.org/10.1038/bmt.2017.2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.2

This article is cited by

Search

Advanced search

Quick links